Compass Pathways Confirms Rapid, Durable Antidepressant Effects in Six-Month Phase 3 Trial
CMPS•Compass Pathways reported six-month follow-up data from its second Phase 3 COMP360 psilocybin trial, confirming rapid antidepressant response within weeks. The data showed durable symptom remission through six months post-treatment, reinforcing its therapeutic profile for treatment-resistant depression.
1. Six-Month Follow-Up Results
Compass Pathways announced that six-month data from its second Phase 3 COMP360 psilocybin trial demonstrated rapid onset of antidepressant effect within weeks and sustained efficacy through 24 weeks, addressing durability concerns in treatment-resistant depression.
2. Trial Design and Patient Cohort
The multicenter, randomized, double-blind study enrolled adults with treatment-resistant depression who received a single 25 mg dose of COMP360 alongside structured psychotherapy, with remission assessed at six weeks and durability evaluated through month six.
3. Implications and Next Steps
The durable efficacy profile supports Compass Pathways’ regulatory strategy, with full datasets slated for presentation at upcoming medical conferences and potential health authority submissions by year-end.
